Skip to main content
Figure 1 | Breast Cancer Research

Figure 1

From: Patient-derived breast tumor xenografts facilitating personalized cancer therapy

Figure 1

Schematic of preclinical clinical trials: from classification to patient selection for clinical trials. Based on the advances in generating patient-derived xenografts and breast cancer subtyping, preclinical trials can be designed to provide subtype-specific outcome data and to identify molecular profiles of tumors that respond to specific therapies, thus having the potential to better guide patient selection for clinical trials and to reduce costs and ineffective treatment options for patients. Patient-derived xenografts are subtyped by standard immunohistochemistry (IHC) and by molecular profiling and then placed on each arm of a preclinical clinical trial for direct comparison of treatment strategies. The treatment response is then correlated with subtype classification to identify the responsive versus non-responsive tumor subtypes that correspond to patient tumor subtypes to guide selection for clinical trials.

Back to article page